Cancer, a word that strikes a chord of fear in many, is a fighting word. At $47.7bn, cancer is one of the largest, fastest growing markets in the pharmaceutical industry, and while it is a match we have yet to win, researchers and scientists have on their boxing gloves and are staying in the fight.
Cancer drug sales are slowing down in the U.S., Reuters reported Monday.
EpiCept’s lead product, Ceplene, is approved for marketing in the EU for the maintenance of first remission in patients with acute myeloid leukemia.
The information could allow researchers to observe cellular changes as a patient undergoes cancer treatment, and could aid in the development of new molecular therapeutics for diseases such as cancer.
“Programmed cell death” sounds a bit sinister, but it’s actually a normal and healthy process.